Puma Biotech Raises 2026 Outlook as NERLYNX Demand Drives Q2 Beat
PBYI has more than doubled off its 52-week low of $3.05.
Summary
Puma Biotechnology reported Q2 revenue of $56.5M and adjusted EPS of $0.20, beating the single-analyst estimate of $0.04. The company raised its full-year 2026 net product revenue guidance to $205–209M from $202–206M and net income to $17–20M from $16–19M, citing increased NERLYNX demand. This follows a June shareholder vote rejecting an extension of the CEO's warrant for 2.1M shares, which had raised governance concerns. The guidance raise and strong commercial execution signal improving fundamentals for the breast cancer drug. With a market cap around $413M and shares at $8.12, the stock trades at 33x forward earnings, well above the median analyst target of $5.00. Q3 revenue is guided to $56–59M, suggesting continued momentum.
At the time of this announcement, PBYI was trading at $8.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $413.3M. The 52-week trading range was $3.05 to $8.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.